So grateful and honoured to be awarded a Blood Cancer UK @BloodCancer_Res Early Career Advancement Fellowship. Excited to be involved with this fantastic charity in our shared effort to beat blood cancers. @SCICambridge https://t.co/uKSW0VEPuE
‼️ New postdoc opportunity in my group to work on a project funded by @EHA_Hematology investigating the immune microenvironment in AML.
📅 Closing date: 05/01/2026
👉 Full details and how to apply: https://t.co/sOrkJsJ2nb
Please RT and get in touch if interested! 👩💻
Ferroptosis and 🩸 stem cell biology have a lot to say to each other... Hoping this work inspires #ferroptosis researchers to explore HSCs and #hematopoiesis researchers to lean into ferroptosis 🤝
Have you been affected by Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS)? Could you take part in research to improve access to Stem Cell Transplants - more info on flyers & here 👉🏻https://t.co/nw9LSMIqtP
@NHSBT@DonorHealthBTRU
🧨Exciting new pre-print! Introducing ppmSeq - cost effective, scalable dual-strand 🧬 sequencing. Scalability & ultra-low error in one! A game changer for somatic genome discovery science and cfDNA clinical apps. Check out thread for deets! @AlexandrePCheng@UltimaGenomics
Love Epigenetics? We’re hiring a 2-yr postdoc in stem cell & chromatin biology @SAiGENCI (Uni of Adelaide)! Work with cutting-edge genomics + world-class collaborators. https://t.co/xeIyUNmNPY
We are recruiting….Any clinician interested in doing a PhD in London on lymphoma and mechanisms of transformation/ TME….please apply (and get in touch with us)
Game-changing news for blood cancer patients! Thanks to new legislation, personalised treatments including CAR-T therapy can now be made on-site in hospitals, meaning they can reach patients faster and closer to home. 👏
Read more: https://t.co/BiPwc7yKBq
Delighted to have our preprint led by @lvchosen1 up: Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells
https://t.co/nMP5Xd7aEY
🧵 below ...
Come join a blossoming blood cancer research network here at @SussexUni which has just added its 10th group leader.
Awesome opportunity to work alongside Dr @oberoi_jasmeen who will be a great mentor. All in a very supportive research institute and a beautiful region of the UK.
High-risk RUNX1 and STAG2, but not low-risk TET2, mutations selectively expand different compartments of SF3B1-mutant primitive HSPCs. https://t.co/UGDvJUJzKk #myeloidneoplasia
So grateful and honoured to be awarded a Blood Cancer UK @BloodCancer_Res Early Career Advancement Fellowship. Excited to be involved with this fantastic charity in our shared effort to beat blood cancers. @SCICambridge https://t.co/uKSW0VEPuE